Hubei Goto Biopharm Co.,Ltd.
SZSE:300966.SZ
21.06 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|
Revenue
| 566.399 | 604.571 | 590.885 | 468.117 | 464.802 | 437.302 | 333.692 |
Cost of Revenue
| 441.279 | 466.352 | 434.975 | 361.494 | 333.114 | 306.327 | 231.702 |
Gross Profit
| 125.121 | 138.22 | 155.911 | 106.624 | 131.688 | 130.975 | 101.99 |
Gross Profit Ratio
| 0.221 | 0.229 | 0.264 | 0.228 | 0.283 | 0.3 | 0.306 |
Reseach & Development Expenses
| 38.099 | 45.147 | 37.123 | 21.604 | 26.056 | 27.104 | 23.464 |
General & Administrative Expenses
| 16.76 | 15.075 | 18.53 | -6.118 | -40.602 | -29.605 | -14.629 |
Selling & Marketing Expenses
| 7.065 | 4.907 | 5.471 | 3.454 | 4.467 | 4.273 | 3.341 |
SG&A
| 23.825 | 19.982 | 24.001 | -2.664 | -36.135 | -25.331 | -11.288 |
Other Expenses
| -0.414 | -0.39 | 23.405 | 10.065 | 36.658 | 31.961 | 19.093 |
Operating Expenses
| 83.354 | 85.29 | 83.473 | 40.705 | 38.843 | 44.293 | 39.988 |
Operating Income
| 19.53 | 38.904 | 62.712 | 57.3 | 79.695 | 78.333 | 55.209 |
Operating Income Ratio
| 0.034 | 0.064 | 0.106 | 0.122 | 0.171 | 0.179 | 0.165 |
Total Other Income Expenses Net
| -0.414 | -0.39 | 23.405 | 2.942 | 3.117 | 2.053 | 0.432 |
Income Before Tax
| 19.116 | 38.514 | 86.117 | 60.242 | 82.811 | 80.386 | 55.642 |
Income Before Tax Ratio
| 0.034 | 0.064 | 0.146 | 0.129 | 0.178 | 0.184 | 0.167 |
Income Tax Expense
| -2.174 | -0.982 | 8.051 | 7.047 | 9.815 | 9.708 | 8.203 |
Net Income
| 23.005 | 40.205 | 78.331 | 53.289 | 72.996 | 70.678 | 47.439 |
Net Income Ratio
| 0.041 | 0.067 | 0.133 | 0.114 | 0.157 | 0.162 | 0.142 |
EPS
| 0.2 | 0.35 | 0.68 | 0.46 | 0.63 | 0.84 | 1.03 |
EPS Diluted
| 0.2 | 0.35 | 0.68 | 0.46 | 0.63 | 0.84 | 1.03 |
EBITDA
| 72.63 | 82.906 | 118.606 | 96.423 | 128.145 | 120.615 | 86.704 |
EBITDA Ratio
| 0.128 | 0.137 | 0.201 | 0.206 | 0.276 | 0.276 | 0.26 |